Business Description
Omnicell Inc
NAICS : 621999
SIC : 8099
ISIN : US68213N1090
Share Class Description:
FRA:OC9: Ordinary SharesDescription
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.95 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | 10.81 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.72 | |||||
| Beneish M-Score | -2.89 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.5 | |||||
| 3-Year EBITDA Growth Rate | -18.2 | |||||
| 3-Year EPS without NRI Growth Rate | 37.2 | |||||
| 3-Year FCF Growth Rate | -2.3 | |||||
| 3-Year Book Growth Rate | 4.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 2.02 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.98 | |||||
| 9-Day RSI | 66.72 | |||||
| 14-Day RSI | 66.12 | |||||
| 6-1 Month Momentum % | 36.69 | |||||
| 12-1 Month Momentum % | 33.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | |||||
| Quick Ratio | 0.95 | |||||
| Cash Ratio | 0.59 | |||||
| Days Inventory | 60.07 | |||||
| Days Sales Outstanding | 86.84 | |||||
| Days Payable | 27.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.1 | |||||
| Shareholder Yield % | 0.11 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40.84 | |||||
| Operating Margin % | -3.33 | |||||
| Net Margin % | -1.66 | |||||
| FCF Margin % | 11.17 | |||||
| ROE % | -1.47 | |||||
| ROA % | -0.78 | |||||
| ROIC % | -2.26 | |||||
| 3-Year ROIIC % | -19.95 | |||||
| ROC (Joel Greenblatt) % | -17.23 | |||||
| ROCE % | -2.01 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 28.38 | |||||
| PE Ratio without NRI | 34.22 | |||||
| Shiller PE Ratio | 65.7 | |||||
| Price-to-Owner-Earnings | 36.63 | |||||
| PS Ratio | 2.11 | |||||
| PB Ratio | 1.83 | |||||
| Price-to-Tangible-Book | 7.5 | |||||
| Price-to-Free-Cash-Flow | 18.98 | |||||
| Price-to-Operating-Cash-Flow | 13.22 | |||||
| EV-to-EBIT | -64.47 | |||||
| EV-to-EBITDA | 40.9 | |||||
| EV-to-Revenue | 2.15 | |||||
| EV-to-Forward-Revenue | 3.82 | |||||
| EV-to-FCF | 19.32 | |||||
| Price-to-Projected-FCF | 1.14 | |||||
| Price-to-Median-PS-Value | 0.75 | |||||
| Price-to-Graham-Number | 3.38 | |||||
| Earnings Yield (Greenblatt) % | -1.55 | |||||
| FCF Yield % | 5.25 | |||||
| Forward Rate of Return (Yacktman) % | -15.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Omnicell Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 975.418 | ||
| EPS (TTM) (€) | -0.361 | ||
| Beta | 0.32 | ||
| Volatility % | 69.54 | ||
| 14-Day RSI | 66.12 | ||
| 14-Day ATR (€) | 1.149945 | ||
| 20-Day SMA (€) | 40.77 | ||
| 12-1 Month Momentum % | 33.8 | ||
| 52-Week Range (€) | 23.4 - 48.2 | ||
| Shares Outstanding (Mil) | 45.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Omnicell Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Omnicell Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Omnicell Inc Frequently Asked Questions
What is Omnicell Inc(FRA:OC9)'s stock price today?
The current price of FRA:OC9 is €45.80. The 52 week high of FRA:OC9 is €48.20 and 52 week low is €23.40.
When is next earnings date of Omnicell Inc(FRA:OC9)?
The next earnings date of Omnicell Inc(FRA:OC9) is 2025-02-07 Est..
Does Omnicell Inc(FRA:OC9) pay dividends? If so, how much?
Omnicell Inc(FRA:OC9) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers